News
We send the latest information from SMC Laboratories.
New Model Launch: Introduction of the Rat CCl₄-Induced Acute Liver Injury Model
SMC Laboratories is pleased to announce the launch of a new in vivo platform: the rat CCl₄ (carbon tetrachloride)-induced acute liver injury model. This model reproduces acute hepatocellular injury and is well-suited for the non-clinical evaluation of compounds with hepatoprotective or anti-inflammatory properties. Following a single intraperitoneal administration of CCl₄, serum ALT and AST levels…
Launch of Rat Disease Model Services
To better meet evolving research needs, SMC Laboratories has officially launched a lineup of preclinical rat disease models across multiple therapeutic areas. ■ Background of Rat Model Introduction We have observed a significant rise in inquiries for rat-based studies due to the following reasons: Larger body size of rats allows for increased sample volume per…
Chitinase-1 Inhibition Attenuates MASH Progression: A Novel Therapeutic Approach via Metabolic Reprogramming
In May 2025, a collaborative research team from OncoArendi Therapeutics and academic institutions in Poland published a study in Frontiers in Immunology highlighting the therapeutic potential of the CHIT1 inhibitor OATD-01. Using multiple MASH (metabolic dysfunction-associated steatohepatitis) models, including the STAM™ mouse, the study demonstrated that OATD-01 can modulate macrophage metabolism and suppress disease progression….
Exhibition Announcement: SMC Laboratories to Exhibit at the 61st Annual Meeting of the Japan Society of Hepatology
SMC Laboratories, Inc. is pleased to announce our participation in the 61st Annual Meeting of the Japan Society of Hepatology, to be held on June 5–6, 2025, at Hotel New Otani, Tokyo. We will once again be showcasing our preclinical models, including the STAM™ mouse for MASH and MASH-HCC, along with other inflammation- and…
Hepatocellular Senescence Linked to Liver Cancer Development: Sirolimus Shows Preventive Potential in Preclinical Study
A new study published in Human Cell by researchers at the University of Nottingham highlights the role of hepatocellular senescence in the progression to hepatocellular carcinoma (HCC). The study further demonstrates that sirolimus, an mTOR inhibitor, can prevent HCC development by suppressing the secretion of senescence-associated secretory phenotype (SASP) factors. The team analyzed liver…
IL-18 Binding Protein Shows Promise in Suppressing Fibrosis in MASH: New Study Published in Cell Reports Medicine
A recent study published in Cell Reports Medicine (April 2025) reports that treatment with an IL-18 binding protein (IL-18BP) significantly suppresses the progression of fibrosis in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight IL-18BP as a potential new therapeutic strategy for managing MASH. In this preclinical study, IL-18BP was administered…
Devonian Reports Positive Results in MASH Liver Study
In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse. Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…
New possibilities for MASH treatment: Confirmation of the effectiveness of 2-hydroxybenzylamine
A new study published in the Feb 2025 issue of Nutrients highlights the therapeutic promise of 2-hydroxybenzylamine (2-HOBA) in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The research demonstrates that 2-HOBA effectively scavenges reactive dicarbonyl compounds, leading to reduced hepatic inflammation and fibrosis, and improved liver function. In this study, MASH model mice were treated…
CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies
In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstrating the efficacy of leronlimab (a CCR5 antagonist) in liver disease models. Using our STAM (MASH-HCC) and CCl₄-induced liver fibrosis models, leronlimab monotherapy successfully reversed liver fibrosis—an area with significant unmet medical need. These findings suggest that leronlimab’s anti-fibrotic…
A New Approach to Pulmonary Fibrosis Research: Introducing SMC Laboratories’ IPF Model
SMC Laboratories, Inc. (Tokyo, Japan) is a preclinical CRO specializing in pharmacological evaluations using disease animal models. We are pleased to highlight our enhanced service offering for drug development in pulmonary fibrosis: the Idiopathic Pulmonary Fibrosis (IPF) model. ■ Low-Stress Monitoring with SpO₂ Measurement We have recently introduced SpO₂ (oxygen saturation) monitoring using a pulse…